Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer

In patients with advanced or recurrent endometrial cancer, the addition of pembrolizumab to standard chemotherapy resulted in significantly longer progression-free survival than with chemotherapy alone.

Uloženo v:
Podrobná bibliografie
Vydáno v:The New England journal of medicine Ročník 388; číslo 23; s. 2159 - 2170
Hlavní autoři: Eskander, Ramez N., Sill, Michael W., Beffa, Lindsey, Moore, Richard G., Hope, Joanie M., Musa, Fernanda B., Mannel, Robert, Shahin, Mark S., Cantuaria, Guilherme H., Girda, Eugenia, Mathews, Cara, Kavecansky, Juraj, Leath, Charles A., Gien, Lilian T., Hinchcliff, Emily M., Lele, Shashikant B., Landrum, Lisa M., Backes, Floor, O’Cearbhaill, Roisin E., Al Baghdadi, Tareq, Hill, Emily K., Thaker, Premal H., John, Veena S., Welch, Stephen, Fader, Amanda N., Powell, Matthew A., Aghajanian, Carol
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States Massachusetts Medical Society 08.06.2023
Témata:
Antibodies, Monoclonal, Humanized - administration & dosage
Antibodies, Monoclonal, Humanized - adverse effects
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cancer
Cancer therapies
Carboplatin
Carboplatin - administration & dosage
Carboplatin - adverse effects
Chemotherapy
Cytotoxicity
DNA Mismatch Repair
Double-Blind Method
Endometrial cancer
Endometrial Neoplasms - drug therapy
Endometrial Neoplasms - genetics
Endometrial Neoplasms - mortality
Endometrial Neoplasms - pathology
Endometrium
Female
Gynecologic Oncology
Gynecology
Hematology
Humans
Hypotheses
Immunotherapy
Laboratories
Mismatch repair
Monoclonal antibodies
Obstetrics
Oncology
Paclitaxel
Paclitaxel - administration & dosage
Paclitaxel - adverse effects
Pembrolizumab
Placebos
Statistical analysis
Survival
Targeted cancer therapy
Treatments in Oncology
Tumors
Japan
ISSN:0028-4793, 1533-4406, 1533-4406
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:In patients with advanced or recurrent endometrial cancer, the addition of pembrolizumab to standard chemotherapy resulted in significantly longer progression-free survival than with chemotherapy alone.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa2302312